Personal information

Activities

Employment (1)

Fondazione IRCCS Policlinico San Matteo: Pavia, IT

Consultant (Center for the Study of Myelofibrosis)
Employment
Source: Self-asserted source
Giovanni Barosi

Works (20)

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood
2024-10-24 | Journal article
Contributors: Ayalew Tefferi; Giovanni Barosi; Francesco Passamonti; Juan-Carlos Hernandez-Boluda; Prithviraj Bose; Konstanze Döhner; Martin Ellis; Naseema Gangat; Jacqueline S. Garcia; Heinz Gisslinger et al.
Source: check_circle
Crossref

Circulating Polymorphonuclear Myeloid-Derived Suppressor Cells (PMN-MDSCs) Have a Biological Role in Patients with Primary Myelofibrosis

Cancers
2024-07 | Journal article | Author
Contributors: Rita Campanelli; Adriana Carolei; Paolo Catarsi; Carlotta Abbà; Emanuela Boveri; Marco Paulli; Raffaele Gentile; Monica Morosini; Riccardo Albertini; Stefania Mantovani et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression?

Blood Cancer Journal
2024-01-23 | Journal article
Contributors: Giovanni Barosi; Rita Campanelli; Paolo Catarsi; Carlotta Abbà; Adriana Carolei; Margherita Massa; Robert Peter Gale; Vittorio Rosti
Source: check_circle
Crossref

JAK2V617F and ischemic stroke: CHIP or CMD-NBV?

Blood Advances
2023-12-12 | Journal article
Contributors: Giovanni Barosi; Vittorio Rosti; Robert Peter Gale
Source: check_circle
Crossref

VEGFA rs3025039 is associated with phenotype severity of myelofibrosis‐type megakaryocyte dysplasia

eJHaem
2023-08 | Journal article
Contributors: Giovanni Barosi; Paolo Catarsi; Rita Campanelli; Margherita Massa; Adriana Carolei; Carlotta Abbà; Annalisa de Silvestri; Robert Peter Gale; Vittorio Rosti
Source: check_circle
Crossref

Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives

Leukemia
2023-04 | Journal article
Contributors: Giovanni Barosi; Vittorio Rosti; Robert Peter Gale
Source: check_circle
Crossref

Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story

Blood Advances
2022-04-12 | Journal article
Contributors: Giovanni Barosi; Robert Peter Gale
Source: check_circle
Crossref

Everyone is entitled to his or her own opinion but not to their own facts*

British Journal of Haematology
2022-03 | Journal article
Contributors: Giovanni Barosi; Robert Peter Gale
Source: check_circle
Crossref

Primary myelofibrosis: rs2010963 VEGFA polymorphism favors a prefibrotic phenotype and is associated with higher risk of thrombosis

Leukemia Research
2021-12 | Journal article
Contributors: Laura Villani; Vittorio Rosti; Margherita Massa; Rita Campanelli; Paolo Catarsi; Adriana Carolei; Carlotta Abbà; Annalisa De Silvestri; Robert Peter Gale; Giovanni Barosi
Source: check_circle
Crossref

VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis

TH Open
2021-10 | Journal article
Contributors: Laura Villani; Vittorio Rosti; Margherita Massa; Rita Campanelli; Paolo Catarsi; Adriana Carolei; Carlotta Abbà; Annalisa de Silvstri; Robert Peter Gale; Giovanni Barosi
Source: check_circle
Crossref

New Markers of Disease Progression in Myelofibrosis

Cancers
2021-10-23 | Journal article
Contributors: Rita Campanelli; Margherita Massa; Vittorio Rosti; Giovanni Barosi
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Clinical Relevance of <i>VEGFA</i> (rs3025039) +936 C&gt;T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes

Genes
2021-08 | Journal article | Author
Contributors: Laura Villani; Adriana Carolei; Vittorio Rosti; Margherita Massa; Rita Campanelli; Paolo Catarsi; Carlotta Abbà; Robert Peter Gale; Giovanni Barosi
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

Impact of the rs1024611 Polymorphism of <i>CCL2</i> on the Pathophysiology and Outcome of Primary Myelofibrosis

Cancers
2021-05 | Journal article | Author
Contributors: Elena Masselli; Cecilia Carubbi; Giulia Pozzi; Antonio Percesepe; Rita Campanelli; Laura Villani; Giuliana Gobbi; Sabrina Bonomini; Giovanni Roti; Vittorio Rosti et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Leukemia
2021-04 | Journal article
Contributors: Onima Chowdhury; Jennifer O’Sullivan; Nikolaos Barkas; Guanlin Wang; Gemma Buck; Angela Hamblin; Ayalew Tefferi; Haifa K. Al-Ali; Giovanni Barosi; Timothy Devos et al.
Source: check_circle
Crossref

Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis

Leukemia
2021-02 | Journal article
Contributors: Giovanni Barosi; Vittorio Rosti; Paolo Catarsi; Laura Villani; Carlotta Abbà; Adriana Carolei; Umberto Magrini; Robert Peter Gale; Margherita Massa; Rita Campanelli
Source: check_circle
Crossref

Plasma sIL-2Rα levels are associated with disease progression in myelofibrosis with JAK2V617F but not CALR mutation

Leukemia Research
2020-03 | Journal article
Contributors: Giovanni Barosi; Rita Campanelli; Paolo Catarsi; Mara De Amici; Carlotta Abbà; Gianluca Viarengo; Laura Villani; Robert P. Gale; Vittorio Rosti; Margherita Massa
Source: check_circle
Crossref

Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology

Leukemia Research
2019-06 | Journal article
Contributors: Pier Luigi Zinzani; Alessandro Rambaldi; Gianluca Gaidano; Corrado Girmenia; Monia Marchetti; Fabrizio Pane; Sante Tura; Giovanni Barosi
Source: check_circle
Crossref

Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis

Blood Advances
2019-06-11 | Journal article
Contributors: Alessandra Carobbio; Alberto Ferrari; Arianna Masciulli; Arianna Ghirardi; Giovanni Barosi; Tiziano Barbui
Source: check_circle
Crossref

Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms

Biology of Blood and Marrow Transplantation
2019-05 | Journal article
Contributors: Pritesh R. Patel; Vitalyi Senyuk; Natalie S. Rodriguez; Annie L. Oh; Elisa Bonetti; Dolores Mahmud; Gianni Barosi; Nadim Mahmud; Damiano Rondelli
Source: check_circle
Crossref

Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations

Blood Reviews
2019-03 | Journal article
Contributors: Corrado Girmenia; Michele Cavo; Massimo Offidani; Francesco Scaglione; Alessandro Corso; Francesco Di Raimondo; Pellegrino Musto; Maria Teresa Petrucci; Giovanni Barosi
Source: check_circle
Crossref

Peer review (17 reviews for 4 publications/grants)

Review activity for Annals of hematology. (1)
Review activity for BMJ case reports. (1)
Review activity for International journal of environmental research and public health (1)
Review activity for Leukemia (14)